Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is underpriced on P/E, of fair value on EV/EBITDA
Target Price
The average target price of PBYI is 3.5 and suggests 47% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr
Buy
Sell